CLINICAL GENOMICS: YOUR PARTNER IN EARLIER DETECTION.

InSure® ONE™ is a highly accurate test for detecting blood in fecal samples.

COLVERA® is a liquid biopsy test designed to detect early recurrence of colorectal cancer.

InSure ONE

InSure ONE is an easy, one-day fecal immunochemical test that uses a sample of water collected with a brush to detect lower GI bleeding.

DETECTING RESIDUAL DISEASE

COLVERA is a clinically validated circulating tumor DNA (ctDNA) blood test designed to detect residual disease after surgical resection in CRC patients.

RECURRENCE MONITORING

COLVERA is a clinically validated ctDNA blood test designed to detect recurrent disease after primary treatment in CRC patients.

TECHNOLOGY

Clinical Genomics harnesses breakthrough science to create innovative and accessible ways to detect disease and enhance lives.

COMPANY

Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management.

CONTACT US

For more information about Clinical Genomics and our products.

Clinical Genomics Pathology Inc. receives licensure from State of California Department of Public Health

Clinical Genomics Pathology Inc. receives licensure from State of California Department of Public Health Bridgewater, NJ – Thursday June 14, 2018 Clinical Genomics, a leading provider of colorectal cancer testing and solutions, is pleased to announce that...

Biotech with Liquid Biopsy for Colorectal Cancer Secures $26 Million in New Funding

Biotech with Liquid Biopsy for Colorectal Cancer Secures $26 Million in New Funding Bridgewater, NJ – Friday June 1, 2018 Clinical Genomics Technologies Pty Ltd (CG), a leading provider of CRC testing solutions, has completed a $26 million financing. The...

Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society

Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society May 30, 2018 The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a...

Clinical Genomics Presents Clinical Utility Data for COLVERA™ at 2018 ASCO Annual Meeting

Clinical Genomics Presents Clinical Utility Data for COLVERA™ at 2018 ASCO Annual Meeting Bridgewater, N.J. – May 24, 2018 Clinical Genomics, a leading provider of colorectal cancer (CRC) testing and solutions, today announced that data demonstrating the...

Social Icons

Facebook Twitter LinkedIn

Copyright © 2018 Clinical Genomics Technologies Pty Ltd. All Rights Reserved.